Drugs / ION440
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06430385 | Oct 2024 → Sep 2027 expected | chromosome Xq28 duplication syndrome | Ionis Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ION440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06430385 ↗ |
| Route | Intrathecal | “administered by intrathecal bolus (ITB) injection.” NCT06430385 ↗ |